



# 2024 AGENT™ Inpatient Coding & Payment Quick Reference

## New ICD-10 PCS Procedure Codes Effective 10/1/2024

Hospital inpatient claims must contain the appropriate ICD-10-PCS code(s) to indicate the services that performed. The table below contains a list of possible ICD-10-PCS codes that may be used to bill for AGENT coronary interventions.

The new ICD-10-PCS codes are designated as non-OR they will need to be reported in addition to the primary coronary intervention ICD-10-PCS code for appropriate DRG assignment.

## Table 1 Updated ICD-10-PCS Codes and Descriptions

ICD-10 PCS code	Description
XW0J3HA	Introduction of paclitaxel-coated balloon technology, one balloon into coronary artery, one artery, percutaneous approach, new technology group 10
ALELOWX	Introduction of paclitaxel-coated balloon technology, two balloons into coronary artery, one artery, percutaneous approach, new technology group 10
XW0J3KA	Introduction of paclitaxel-coated balloon technology, three balloons into coronary artery, one artery, percutaneous approach, new technology group 10
XW0J3LA	Introduction of paclitaxel-coated balloon technology, four or more balloons into coronary artery, one artery, percutaneous approach, new technology group 10
XW0K3HA	Introduction of paclitaxel-coated balloon technology, one balloon into coronary artery, two arteries, percutaneous approach, new technology group 10
XW0K3JA	Introduction of paclitaxel-coated balloon technology, two balloons into coronary artery, two arteries, percutaneous approach, new technology group 10
XW0K3KA	Introduction of paclitaxel-coated balloon technology, three balloons into coronary artery, two arteries, percutaneous approach, new technology group 10
XW0K3LA	Introduction of paclitaxel-coated balloon technology, four or more balloons into coronary artery, two arteries, percutaneous approach, new technology group 10
XW0L3HA	Introduction of paclitaxel-coated balloon technology, one balloon into coronary artery, three arteries, percutaneous approach, new technology group 10
XW0L3JA	Introduction of paclitaxel-coated balloon technology, two balloons into coronary artery, three arteries, percutaneous approach, new technology group 10

(continues)



## **Table 1 Updated ICD-10-PCS Codes and Descriptions** (continued)

ICD-10 PCS code	Description		
XW0L3KA	Introduction of paclitaxel-coated balloon technology, three balloons into coronary artery, three arteries, percutaneous approach, new technology group 10		
XW0L3LA	Introduction of paclitaxel-coated balloon technology, four or more balloons into coronary artery, three arteries, percutaneous approach, new technology group 10		
XW0M3LA	Introduction of paclitaxel-coated balloon technology, four or more balloons into coronary artery, four or more arteries, percutaneous approach, new technology group 10		

## Hospital Inpatient Payment - Medicare

MS-DRG assignment is based on a combination of the diagnoses and procedure codes reported. While MS-DRGs listed in this guide represent likely assignments, Boston Scientific cannot guarantee assignment to any one specific MS-DRG.

All rates shown are 2024 Medicare national averages; actual rates will vary geographically and/or by individual facility.

Table 2 Possible MS-DRG Assignment and Rates

MS-DRG assignment	Description	MS-DRG rate		
PCI without intraluminal device + AGENT DCB				
250	PCI without intraluminal device w MCC	\$ 16,459		
251	PCI without intraluminal device w/o MCC	\$ 11,111		
PCI with intraluminal device + AGENT DCB				
321	PCI with intraluminal device w MCC or 4+arteries	\$ 20,127		
322	PCI with intraluminal device w/o MCC	\$ 12,767		
Procedures with Intravascular Lithotripsy (IVL) + AGENT DCB				
323	Coronary IVL with intraluminal device w MCC	\$ 28,987		
324	Coronary IVL with intraluminal device w/o MCC	\$ 20,785		
325	Coronary IVL without intraluminal device w/o CC/MCC	\$ 18,514		



If you have questions or would like additional information, please email: IC.Reimbursement@BSCI.com

## **Important Information**

Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services rendered. It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA approved label.

Information included herein is current as of January 2024 but is subject to change without notice. Rates for services are effective January 1, 2023.

Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements. The coding options listed within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options.

This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for selecting the site of service and treatment modalities appropriate for the patient based on medically appropriate needs of that patient and the independent medical judgement of the HCP.

#### References

1. CMS. FY2025 Hospital Inpatient Prospective Payment System, CMS-1808-F

### Sequestration Disclaimer

Rates referenced in these guides do not reflect Sequestration, automatic reductions in federal spending that will result in a 2% across-the-board reduction to ALL Medicare rates as of January 1, 2024.

### **CPT®** Disclaimer

Current Procedural Terminology (CPT) © 2024 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions apply to government use. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.